Genmab — Maj 2024

[lahn1]

In Vivo and Ex Vivo Efficacy: Hexabody-CD38 has demonstrated strong anti-tumor activity in patient-derived xenograft (PDX) models and primary MM cells, including those from DARA-refractory patients, indicating its potential effectiveness in a clinical setting.

[lahn1]

Relief of Immune Suppression: Hexabody-CD38 strongly inhibits CD38 cyclase activity, which is hypothesized to relieve immune suppression in the tumor microenvironment, providing an additional therapeutic benefit.

[lahn1]

In summary, the combination of enhanced CDC, robust multi-faceted mechanisms of action, effectiveness in lower CD38 expression levels, and promising preclinical results all suggest that Hexabody-CD38 should help patients who are resistant to Darzalex. The ongoing clinical trials will provide further validation of its safety and efficacy in this patient population.

[lahn1]

Alle patienter på Dara progresserjo desværre så mener det er meget relevant on Hexabody-cd38 virker hvis ikke JnJ opter ind.

[E_L]

can you also ask AI what the share price will be at the end of the year, given these conclusions?

[E_L]

ASCO LBA out: Subcutaneous amivantamab vs intravenous amivantamab https://meetings.asco.org/abstracts-presentations/232405 . seems like a slam dunk.

[Sukkeralf]

Do we know for sure if Genmab gets the same royalty for
an sc version of amivantamab?

[E_L]

wtf I see Volume
704,391shares on Yahoo, is that correct

[E_L]

no i am not sure about that, i think once there was a question on the Q&A on this if i am not mistaken after Dara and Genmab answered something like 'all other contracts are fine'? anyone remember?

[mobbyduck1]

end of the q2 EL

[mobbyduck1]

last day.crazy volume

[Sukkeralf]

Yes - but do we believe that. Jan said the same about sc dara in the b
eginning

[E_L]

no its only month end, not Q end yet

[E_L]

i don't know what to believe anymore... at least now they know how to do an arbitration correct this time around...

[E_L]

talking about arbitration; we haven't seen volume like this in years; last time bigger was september 2020 when the arbitration started...

[StockBull]

Jeg kan varmt anbefale, at enhver udtalelse fra nohope tages med et gran salt. Men det ved vi jo.

[E_L]

ASCO24 Preview: A Look at Some of the Cancer Meeting’s Hottest Abstracts https://www.biospace.com/article/asco-2024-preview-a-look-at-some-of-the-cancer-meeting-s-hottest-abstracts

[E_L]

'On June 3, researchers will be presenting Phase II data on Pfizer and Genmab’s Tivdak (tisotumab vedotin) in head and neck squamous cell carcinoma. Analysts from Leerink Partners were encouraged by the data, positing that they “could see antibody drug-conjugates (ADCs) eventually replace chemotherapy in [the] head and neck cancer treatment paradigm, particularly in the second line space,” according to a report.

[E_L]

Additionally, analysts “would be keen to see detail on the tolerability, particularly the avoidance of bleeding events, which had been a concern in previous studies evaluating tisotumab vedotin in head and neck cancer,” according to the report.'

[lahn1]

Ha EL, ville det ikke være dejligt hvis den kunne det Det kan den desværre ikke svare på, men den kan bruges til at analysere tekster og komme med kvalificerede bud på baseret på hvad du har fodre den med.